A phase I trial of intravenous catumaxomab: a bispecific monoclonal antibody targeting EpCAM and the T cell coreceptor CD3
Crossref DOI link: https://doi.org/10.1007/s00280-015-2728-5
Published Online: 2015-03-27
Published Print: 2015-05
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Mau-Sørensen, Morten
Dittrich, Christian
Dienstmann, Rodrigo
Lassen, Ulrik
Büchler, Wilfried
Martinius, Holger
Tabernero, Josep
Text and Data Mining valid from 2015-03-27